iCAD, Inc. (NASDAQ:ICAD – Get Free Report) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 196,800 shares, a growth of 7.6% from the August 31st total of 182,900 shares. Based on an average daily volume of 170,500 shares, the days-to-cover ratio is currently 1.2 days. Approximately 0.8% of the company’s stock are sold short.
iCAD Price Performance
Shares of NASDAQ:ICAD opened at $1.53 on Wednesday. iCAD has a 12 month low of $1.18 and a 12 month high of $2.65. The firm has a market capitalization of $40.61 million, a P/E ratio of -12.75 and a beta of 1.51. The company’s fifty day moving average price is $1.48 and its 200 day moving average price is $1.49.
iCAD (NASDAQ:ICAD – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The technology company reported ($0.07) earnings per share (EPS) for the quarter. The business had revenue of $5.03 million for the quarter. iCAD had a negative return on equity of 13.59% and a negative net margin of 15.67%.
Institutional Trading of iCAD
Analyst Upgrades and Downgrades
Separately, StockNews.com upgraded shares of iCAD from a “sell” rating to a “hold” rating in a research note on Thursday, August 22nd.
View Our Latest Research Report on iCAD
About iCAD
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Articles
- Five stocks we like better than iCAD
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Investing In Automotive Stocks
- 2 Energy Stocks Fueling the AI Datacenter Boom
- What Are the FAANG Stocks and Are They Good Investments?
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.